Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

A novel breath test to directly measure use of vaginal gel and condoms.

van der Straten A, Cheng H, Wasdo S, Montgomery L, Smith-McCune K, Booth M, Gonzalez D, Derendorf H, Morey TE, Dennis DM.

AIDS Behav. 2013 Jul;17(6):2211-21. doi: 10.1007/s10461-012-0390-z.

PMID:
23321948
2.

Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels.

Morey TE, Wasdo S, Wishin J, Quinn B, van der Straten A, Booth M, Gonzalez D, Derendorf H, Melker RJ, Dennis DM.

J Clin Pharmacol. 2013 Jan;53(1):103-11. doi: 10.1177/0091270011434157. Epub 2013 Jan 24.

PMID:
23400750
3.

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.

Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S, Karim SS.

Antivir Ther. 2013;18(3):301-10. doi: 10.3851/IMP2311. Epub 2012 Aug 23.

PMID:
22914267
4.

A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.

Johnson TJ, Clark MR, Albright TH, Nebeker JS, Tuitupou AL, Clark JT, Fabian J, McCabe RT, Chandra N, Doncel GF, Friend DR, Kiser PF.

Antimicrob Agents Chemother. 2012 Dec;56(12):6272-83. doi: 10.1128/AAC.01431-12. Epub 2012 Sep 24.

5.

Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.

MacQueen KM, Weaver MA, van Loggerenberg F, Succop S, Majola N, Taylor D, Karim QA, Karim SA.

AIDS Behav. 2014 May;18(5):826-32. doi: 10.1007/s10461-014-0753-8.

6.

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team.

AIDS. 2006 Feb 28;20(4):543-51.

PMID:
16470118
7.

Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).

Carballo-Diéguez A, Balán IC, Morrow K, Rosen R, Mantell JE, Gai F, Hoffman S, Maslankowski L, El-Sadr W, Mayer K.

AIDS Care. 2007 Sep;19(8):1026-31.

PMID:
17852000
8.

Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews.

Turner AN, De Kock AE, Meehan-Ritter A, Blanchard K, Sebola MH, Hoosen AA, Coetzee N, Ellertson C.

J Clin Epidemiol. 2009 Jul;62(7):759-65. doi: 10.1016/j.jclinepi.2008.07.011. Epub 2008 Nov 14.

PMID:
19013762
9.

A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.

Cohen JA, Brache V, Foster J, Cochon L, Callahan M, Schwartz J.

Sex Transm Dis. 2013 Jun;40(6):476-81. doi: 10.1097/OLQ.0b013e3182927ab1.

PMID:
23677021
10.

HIV/AIDS. At last, vaginal gel scores victory against HIV.

Cohen J.

Science. 2010 Jul 23;329(5990):374-5. doi: 10.1126/science.329.5990.374. Epub 2010 Jul 19. No abstract available.

PMID:
20643914
11.

Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.

Clark MR, Friend DR.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1458-66. doi: 10.1089/AID.2011.0328. Epub 2012 Apr 17.

PMID:
22394281
12.

Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.

Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH; CAPRISA004 TRAPS team.

J Infect Dis. 2012 Oct 1;206(7):993-1001. Epub 2012 Jul 24.

13.

The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection.

Marais D, Gawarecki D, Allan B, Ahmed K, Altini L, Cassim N, Gopolang F, Hoffman M, Ramjee G, Williamson AL.

Antivir Ther. 2011;16(8):1219-26. doi: 10.3851/IMP1890.

PMID:
22155903
14.

Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.

Jacot TA, Nelson A, Thurman A, Kashuba AD, Archer DF, Doncel GF.

PLoS One. 2014 Dec 9;9(12):e114368. doi: 10.1371/journal.pone.0114368. eCollection 2014.

15.

Tenofovir gel--the new HIV prevention 'banker'?

Bateman C.

S Afr Med J. 2007 Jul;97(7):496, 498. Review. No abstract available.

16.

Predicting product adherence in a topical microbicide safety trial in Pune, India.

Tolley EE, Tsui S, Mehendale S, Weaver MA, Kohli R.

AIDS Behav. 2012 Oct;16(7):1808-15.

17.

Microbicides are promoted as offering a 'female-controlled' HIV prevention method: so can they revolutionize the HIV crisis of young women in Kenya?

Raphael MC.

J Public Health (Oxf). 2012 Dec;34(4):625-30. doi: 10.1093/pubmed/fds049. Epub 2012 Oct 10. No abstract available.

PMID:
23055541
18.

Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.

O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR.

Sex Transm Dis. 2010 Feb;37(2):100-4. doi: 10.1097/OLQ.0b013e3181bc0aac.

PMID:
19823111
19.

Changes in condom use during a microbicide clinical trial in Pune, India.

Marlow HM, Tolley EE, Weaver MA, Kohli R, Mehendale S.

AIDS Care. 2012;24(5):539-43. doi: 10.1080/09540121.2011.630343. Epub 2011 Nov 17.

PMID:
22088145
20.

Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report.

Joshi SN, Dutta S, Kumar BK, Katti U, Kulkarni S, Risbud A, Mehendale S.

Sex Transm Infect. 2008 Oct;84(5):343-7. doi: 10.1136/sti.2007.029207. Epub 2008 Apr 21.

PMID:
18426844

Supplemental Content

Support Center